Japan Respiratory Syncytial Virus (RSV) Therapeutics Market was valued at USD 0.3 Billion in 2022 and is projected to reach USD 0.7 Billion by 2030, growing at a CAGR of 10.5% from 2024 to 2030.
Japan's Respiratory Syncytial Virus (RSV) Therapeutics Market: Industry Types and Evolving Requirements
Respiratory Syncytial Virus (RSV) poses a significant health challenge in Japan, particularly among infants and the elderly. The therapeutic landscape for RSV in Japan is rapidly evolving, driven by recent pharmaceutical advancements and a growing demand for effective treatments.
Market Overview
The global RSV therapeutics market has witnessed substantial growth in recent years. In 2023, the market was valued at approximately USD 1.08 billion and is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.78% through 2029. This growth is attributed to increased disease awareness, advancements in virology, and the development of novel therapeutic options.
Recent Approvals and Developments in Japan
Beyfortus (Nirsevimab): In 2024, AstraZeneca and Sanofi's Beyfortus, a long-acting monoclonal antibody, received approval in Japan for the prophylaxis of lower respiratory tract disease caused by RSV in neonates, infants, and children entering their first RSV season. This approval marked a significant advancement in protecting vulnerable pediatric populations.
Arexvy (RSV Vaccine): GSK's Arexvy was initially approved by Japan's Ministry of Health, Labour and Welfare (MHLW) for adults aged 60 and above. Subsequently, in November 2024, the approval was extended to include adults aged 50 to 59 at increased risk of severe RSV disease. This expansion underscores the importance of vaccinating broader age groups to mitigate RSV-related complications.
S-337395 (Oral Antiviral Candidate): Shionogi & Co., Ltd., in collaboration with UBE Corporation, announced positive results from a Phase 2 trial of their investigational oral antiviral candidate, S-337395. This drug targets the RSV L protein, essential for viral replication, and has received Fast Track designation from the U.S. Food and Drug Administration (FDA), highlighting its potential in RSV treatment.
Industry Requirements and Future Directions
The evolving RSV therapeutics market in Japan necessitates continuous innovation and adaptation from pharmaceutical industries. Key requirements include:
Development of Diverse Therapeutic Options: Beyond vaccines and monoclonal antibodies, there is a pressing need for effective antiviral medications that can be administered across various age groups, especially considering the aging population in Japan.
Enhanced Surveillance and Epidemiological Studies: Comprehensive data on RSV incidence, seasonality, and patient outcomes are crucial. Such information guides the development of targeted therapies and informs public health strategies.
Collaboration with Regulatory Bodies: Engaging with authorities like the MHLW ensures that therapeutic developments align with national health priorities and meet safety and efficacy standards.
Public Awareness and Education: Educating healthcare professionals and the public about RSV prevention and treatment options is vital for the successful implementation of new therapeutics.
Conclusion
Japan's RSV therapeutics market is poised for significant growth, driven by recent pharmaceutical innovations and a proactive approach to addressing RSV-related health challenges. The industry's commitment to developing diverse and effective therapeutic options will be instrumental in safeguarding public health against RSV infections.
Get an In-Depth Research Analysis of the Japan Respiratory Syncytial Virus (RSV) Therapeutics Market Size And Forecast [2025-2032]
Roche
AstraZeneca
Merck
AbbVie
Valeant Pharmaceuticals
GlaxoSmithKline
ReViral
Gilead Sciences
Teva Pharmaceutical
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Respiratory Syncytial Virus (RSV) Therapeutics Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Respiratory Syncytial Virus (RSV) Therapeutics Market
Monoclonal Antibodies
Antiviral Drugs
Vaccines
Supportive Care Products
Intravenous (IV)
Subcutaneous (SC)
Inhalation
Oral
Pediatric (Infants and Young Children)
Adult
Elderly
Acute Bronchiolitis
Pneumonia
Chronic Obstructive Pulmonary Disease (COPD)
Immunocompromised Patients
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Clinics
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan Respiratory Syncytial Virus (RSV) Therapeutics Market Research Analysis
1. Introduction of the Japan Respiratory Syncytial Virus (RSV) Therapeutics Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, By Type
6. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, By Application
7. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/